Key Clinical Data And Drug Approvals Expected In 2H 2016
As July is already upon us, Scrip takes a look at some of the more interesting clinical trial read-outs and drug approvals expected clinical trials due to report in the second half of the year.
You may also be interested in...
User fee date for Portola's anticoagulant reversal agent is near, but not soon enough for Medicare's new technology payments in 2017 – while Boehringer's Praxbind gets in in time; BTG's Vistogard also gains the extra payments.
Agency's advisors were divided on whether Valeant's proposal for voluntary registry would suffice or whether mandatory program under REMS was needed to better assess risk of suicide and suicidal behavior with psoriasis drug.
Infinity's hopes for accelerated approval of the PI3K inhibitor based on the DYNAMO study have been dashed, so while it plots a new strategy – with or without partner AbbVie – it cuts discovery R&D staff.